Creo Medical Group PLC
CREO.L operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its customers.
Business. CREO.L is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Headquartered in the United Kingdom, the company is listed on the London Stock Exchange under the ticker symbol CREO.L. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CREO.L is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Headquartered in the United Kingdom, the company is listed on the London Stock Exchange under the ticker symbol CREO.L. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.1, indicating a conservative leverage position. However, the liquidity risk is assessed as low, and the current ratio of 2.75 suggests the company has sufficient short-term assets to cover its liabilities. Despite this, the operating cash flow is negative at -22.2 million GBP, and the free cash flow is also negative at -26.7 million GBP, signaling potential challenges in generating positive cash from operations.
Profitability metrics are concerning, with a return on equity of -67.69% and a return on assets of -44.15%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is significantly negative at -28.8 million GBP, and the net income is also negative at -28.7 million GBP, highlighting the company's current unprofitability.
The company's revenue is concentrated in a single segment, as disclosed in the financial snapshot, with no additional segment details provided. Geographically, the exposure is not specified, but the company's operations are primarily in the healthcare services and equipment sector. The lack of segment and geographic diversification could pose a concentration risk.
The growth trajectory is not clearly defined, as the outlook for the current and next fiscal years is not provided. However, the negative operating and net income figures suggest that the company is not currently experiencing growth. The capital expenditure of -400,000 GBP indicates some investment in long-term assets, but the overall financial performance does not support significant growth.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The dilution potential is also assessed as low, and the company has not made any recent issuances or disclosures that would suggest a high dilution risk. The risk assessment does not identify any significant threats to the company's financial stability.
Recent events, such as filings and transcripts, are not detailed in the provided data. The company's financial performance and risk profile suggest that it is currently facing challenges, but there are no immediate liquidity or dilution concerns. The analyst estimates provide a range of price targets, with a mean of 50.00 GBP and a median of 40.00 GBP, indicating a mixed outlook from analysts.
- The company has a low debt-to-equity ratio, indicating a conservative capital structure.
- The company is currently unprofitable, with significant negative operating and net income.
- The liquidity position is strong, with a current ratio of 2.75, but the operating and free cash flows are negative.
- The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags.
- Analysts have provided a range of price targets, with a mean of 50.00 GBP and a median of 40.00 GBP.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,03 |
| Revenue | —no estimate | —no estimate | 6,0M GBP |
| Operating income | —no estimate | —no estimate | -4,4M GBP |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- CREO.L Market data — financials · 2026-05-27
- Creo Medical Group PLC Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Craig Jonathan GullifordChief Executive Officer, Executive Director